Press Releases

Press Releases

Jun 29, 2022
Positive Data for Istaroxime in Early Cardiogenic Shock Brings Notable Interest from Potential Partners WARRINGTON, Pa. , June 29, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for acute cardiovascular
May 23, 2022
The study met its primary endpoint of improved systolic blood pressure (SBP) profile at 6 hours with the istaroxime group performing significantly better than the control group Increased SBP also persisted through 24 hours The study also met several key secondary endpoints associated with improving
Apr 20, 2022
Company to host conference call following the presentation WARRINGTON, Pa. , April 20, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today
Mar 31, 2022
Company to present on Monday, April 4, 2022 at 11:00 am WARRINGTON, Pa. , March 31, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced that